MedTrace Logo

Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies

NCT00580450 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2007-12-24

No results posted yet for this study

Summary

The purpose of this trial is to determine safety and efficacy of 16 weeks treatment with thymosin alpha 1 given at 1.6 mg dose once daily by subcutaneous injection in adult patients with hematological undergone allogenic bone marrow transplantation and CMV positive.

The efficacy will be explored assessing the ability of thymosin alpha1 to prevent the infection complications.

Conditions

Interventions

DRUG

Thymosin alpha 1

1.6 mg sc once a day for 16 weeks

Sponsors & Collaborators

  • University Of Perugia

    lead OTHER

Principal Investigators

  • Andrea Velardi, Prof · Hematology Section, University of Perugia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2007-12-31
Completion
2010-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00580450 on ClinicalTrials.gov